Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Cancer Type/Condition:  Breast cancer, female
Trial Type:  Treatment
Drug:  trastuzumab
Find trials that include:  Any drugs shown
Trial Status:  Closed
Trial Phase:  Phase III
Results 1-25 of 57 for your search:
Start Over
Phase II/III Randomized Study of Anastrozole With or Without Trastuzumab (Herceptin) in Postmenopausal Women With Hormone-Receptor Positive HER2-Overexpressing Metastatic Breast Cancer
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ROCHE-BO16216, CWRU-030118, GENENTECH-H2223g, ROCHE-1100, ROCHE-B016216F, NCT00022672
Trastuzumab Versus Lapatinib as Neoadjuvant Treatment for Her2+ Patients
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: Over 18
Sponsor: Other
Protocol IDs: GEICAM/2006-14, Nº EudraCT 2007-007031-13, NCT00841828
Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: GBG 66, 2011-000553-23, NCT01426880
Phase III Randomized, Single-Blind Study of Monoclonal Antibody HER2 in Chemotherapy-Naive Metastatic Breast Cancer That Overexpresses HER2/neu (Summary Last Modified 07/98)
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: UCLA-HSPC-9510492, NCI-V96-0947
Paclitaxel With or Without Trastuzumab in Treating Patients With or Without HER-2/Neu Breast Cancer That is Inoperable, Recurrent, or Metastatic
Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-02792, CALGB-9840, U10CA031946, CLB-9840, NCT00003440
Herceptin Followed by Chemotherapy in Treating Women With Metastatic Breast Cancer That Overexpresses HER2
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 to 70
Sponsor: Other
Protocol IDs: SAKK 22/99, SWS-SAKK-22/99, EU-99028, NCT00004935
Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-01849, ECOG-N9831, CAN-NCIC-MA28, SWOG-N9831, MA.28, CALGB-49909, NCCTG-N9831, CDR0000067953, GUMC-00224, N9831, U10CA180821, U10CA025224, NCT00005970
Phase III Randomized Study of Adjuvant Doxorubicin, Cyclophosphamide, and Docetaxel With or Without Trastuzumab (Herceptin) Versus Trastuzumab, Docetaxel, and Either Carboplatin or Cisplatin in Women Who Have Undergone Surgery For HER2-neu-Expressing Node-Positive or High-Risk Node-Negative Breast Cancer
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 to 70
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: AVENTIS-TAX-GMA-302, UCLA-0102006, BCIRG-006, UAB-0106, UAB-F010326012, NCI-G01-1978, NCT00768092
Trastuzumab in Treating Women With Primary Breast Cancer
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: BO16348, BIG-01-01, EU-20216, ROCHE-B016348E, ROCHE-B016348C, EORTC-10011, CAN-NCIC-MA24, IBCSG-28-02, MA24, NCT00045032
Docetaxel and Trastuzumab With or Without Carboplatin in Treating Women With HER2-Positive Breast Cancer
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 to 75
Sponsor: NCI, Other
Protocol IDs: CDR0000257580, P30CA016042, UCLA-0109024, BCIRG-007, ROCHE-UCLA-0109024, GENENTECH-UCLA-0109024, NCI-G02-2116, NCT00047255
Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 to 64
Sponsor: Other
Protocol IDs: UC-0140/0005 - PACS 04, FRE-FNCLCC-PACS-04/0005, EU-20236, PACS04, NCT00054587
S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000334899, S0221, U10CA032102, SWOG-S0221, NCT00070564
Evaluation of the Addition of Herceptin to Standard Chemotherapy in the Neoadjuvant Setting for Operable Breast Cancer
Phase: Phase III
Type: Treatment
Status: Completed
Age: Not specified
Sponsor: Other
Protocol IDs: ID99-146, NCT00038402
Phase III Randomized Study of Vinorelbine With or Without Trastuzumab (Herceptin®) in Women With HER2-Positive Progressive Metastatic Breast Cancer
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: SWOG-S0347, S0347, NCT00103233
TBP Study With Capecitabine Plus Minus Trastuzumab
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: GBG 26, BIG3-05, NCT00148876
ErbB2 Over-expressing Metastatic Breast Cancer Study Using Paclitaxel, Trastuzumab, and Lapatinib
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: EGF104383, NCT00272987
Trial of Myocet in Metastatic Breast Cancer
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 an over
Sponsor: Pharmaceutical / Industry
Protocol IDs: STM01-102, NCT00294996
Lapatinib In Combination With Trastuzumab Versus Lapatinib Monotherapy In Subjects With HER2-positive Metastatic Breast Cancer
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: EGF104900, NCT00320385
Trastuzumab for 6 Months or 1 Year in Treating Women With Nonmetastatic Breast Cancer That Can Be Removed By Surgery
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: CDR0000509793, INCA-PHARE, INCA-RECF0146, EUDRACT-2006-000070-67, PHARE, NCT00381901
A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: BO20231, NCT00391092
THOR Study: A Study of Continued Herceptin (Trastuzumab) in Combination With Second Line Chemotherapy in Patients With HER2 Positive Metastatic Breast Cancer.
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ML18742, NCT00448279
Evaluating the Effect of Candesartan vs Placebo in Prevention of Trastuzumab-associated Cardiotoxicity
Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: M06HER, 2006-001707-11, NCT00459771
A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: NSABP B-41, NCT00486668
Start Over